Immunogenicity of sequential poliovirus vaccination schedules with different strains of poliomyelitis vaccines in Chongqing, China: a cross-sectional survey

Figures & data

Table 1. GMTs of antibody against type I, II and III poliovirus after routine immunization among children of three groups

	PV1^a		PV2^b		PV3^c
Group	GMT (1:)	95%CI	GMT (1:)	95%CI	GMT (1:)	95%CI
A(wIPV-bOPV- bOPV)	1557	1390–1744	20	16–24	977	891–1117
B(sIPV-bOPV- bOPV)	2896	2586–3244	19	15–25	1079	972–1199
C(tOPV-bOPV- bOPV)	930	781–1106	674	589–771	318	274–370
F/H	136.466		461.765		198.037
P	0.000		0.000		0.000
*PA-C	0.000		0.000		0.000
*PB-C	0.000		0.000		0.000
*PA-B	0.000		0.000		0.000

PV = poliovirus; GMTs = geometric mean titers; CI = confidence intervals; sIPV = Sabin strain inactivated polio vaccine; wIPV = Salk strain inactivated polio vaccine; bOPV = bivalent oral polio vaccine; tOPV = trivalent oral polio vaccine.

^aSignificant difference of GMT in PV1 between each two groups based on Wilcoxon test;

^bSignificant difference of GMT in PV2 between wIPV-bOPV- bOPV and tOPV-bOPV- bOPV,sIPV-bOPV- bOPV and tOPV-bOPV- bOPV based on Wilcoxon test;

^cSignificant difference of GMT in PV3 between wIPV-bOPV- bOPV and tOPV-bOPV- bOPV,sIPV-bOPV- bOPV and tOPV-bOPV- bOPV based on Wilcoxon test;

Figure 1. Seroprotection against type I, II and III poliovirus after different routine vaccination schedules. PV1 = type I poliovirus;PV2 = type II poliovirus;PV3 = type III poliovirus; IPV = Sabin strain inactivated polio vaccine; wIPV = Salk strain inactivated polio vaccine; bOPV = bivalent oral polio vaccine; tOPV = trivalent oral polio vaccine. error bar: standard error.(a)Significant difference of seroprotection in PV2 between each two groups;(b)Significant difference of seroprotection in PV3 between sIPV-bOPV- bOPV and tOPV-bOPV- bOPV

Table 2. GMTs against type I, II and III poliovirus after different primary immunization schedules among children in areas with different economical levels

	wIPV-bOPV-bOPV						sIPV-bOPV-bOPV						tOPV-bOPV-bOPV
	PV1		PV2		PV3		PV1		PV2		PV3		PV1		PV2		PV3
Group	GMT	95%CI	GMT	95%CI	GMT	95%CI	GMT	95%CI	GMT	95%CI	GMT	95%CI	GMT	95%CI	GMT	95%CI	GMT	95%CI
H(high economic-level area)	2101	1583–2787	77	43–138	1312	964–1786	2025	1477–2777	167	82–340	1413	1020–1958	925	646–1326	903	712–1144	368	280–482
M(middle economic-level area)	1334	1080–1647	12	9–16	792	647–968	3070	2588–3642	11	8–16	835	711–979	1232	900–1687	976	800–1190	405	319–514
L(low economic-level area)	1523	1318–1759	16	12–20	1045	910–1201	3253	2770–3820	11	9–15	1205	1061–1369	726	566–931	418	335–521	238	185–307
F/H	4.12		29.878		5.367		4.934		40.529		17.838		3.516		19.368		5.266
P	0.017		0.000		0.005		0.008		0.000		0.000		0.031		0.000		0.006
PH-M	0.005		0.000		0.002		0.009		0.000		0.000		0.232		0.659		0.637
PH-L	0.035		0.000		0.132		0.003		0.000		0.417		0.301		0.000		0.032
PM-L	0.309		0.154		0.033		0.652		1.000		0.007		0.008		0.000		0.002

PV1 = type I poliovirus; PV2 = type II poliovirus; PV3 = type III poliovirus; GMTs = geometric mean titers; CI = confidence intervals

Figure 2. Seroprotection against type I, II and III poliovirus after routine vaccination of three schedules in different areas. PV1 = type I poliovirus;PV2 = type II poliovirus;PV3 = type III poliovirus;; sIPV = Sabin strain inactivated polio vaccine; wIPV = Salk strain inactivated polio vaccine; bOPV = bivalent oral polio vaccine; tOPV = trivalent oral polio vaccine. error bar: standard error. There were no significant differences of seroprotection among areas in PV1 and PV3. (a)Significant difference of seroprotection in PV2between high economic level area and middle economic level area. (b) Significant difference of seroprotection in PV2 between high economic level area and low economic level area